Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.
Ketamine has gotten a bad rap as an opioid when there’s plenty of evidence suggesting it isn’t one, Johns Hopkins experts say. They believe this reputation may hamper patients from getting necessary treatment for the kinds of depression that don’t respond to typical antidepressants.
Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist, discusses esketamine nasal spray — a fast-acting treatment for depression that recently was approved by the Food and Drug Administration.
Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression.